Literature DB >> 25974703

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

J K Hicks1, J R Bishop2, K Sangkuhl3, D J Müller4, Y Ji5, S G Leckband6, J S Leeder7, R L Graham8, D L Chiulli9, A LLerena10, T C Skaar11, S A Scott12, J C Stingl13, T E Klein3, K E Caudle14, A Gaedigk7.   

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25974703      PMCID： PMC4512908          DOI： 10.1002/cpt.147

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  36 in total

1.  Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.

Authors:  A LLerena; R Berecz; A de la Rubia; P Fernández-Salguero; P Dorado
Journal:  Ther Drug Monit       Date:  2001-12       Impact factor: 3.681

Review 2.  Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.

Authors:  R Mandrioli; L Mercolini; M A Saracino; M A Raggi
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

Review 4.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 5.  Pharmacogenomics knowledge for personalized medicine.

Authors:  M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2012-10       Impact factor: 6.875

6.  Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.

Authors:  J H Wang; Z Q Liu; W Wang; X P Chen; Y Shu; N He; H H Zhou
Journal:  Clin Pharmacol Ther       Date:  2001-07       Impact factor: 6.875

7.  Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Authors:  Dirk Sibbing; Werner Koch; Daniela Gebhard; Tibor Schuster; Siegmund Braun; Julia Stegherr; Tanja Morath; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati
Journal:  Circulation       Date:  2010-01-18       Impact factor: 29.690

8.  Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.

Authors:  Kazushi Sawamura; Yutaro Suzuki; Toshiyuki Someya
Journal:  Eur J Clin Pharmacol       Date:  2004-09-03       Impact factor: 2.953

9.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875

10.  CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.

Authors:  Marianne Gex-Fabry; Chin B Eap; Beatrice Oneda; Nicola Gervasoni; Jean-Michel Aubry; Guido Bondolfi; Gilles Bertschy
Journal:  Ther Drug Monit       Date:  2008-08       Impact factor: 3.681
View more
  266 in total

Review 1.  Vaccine-Drug Interactions: Cytokines, Cytochromes, and Molecular Mechanisms.

Authors:  Paolo Pellegrino; Cristiana Perrotta; Emilio Clementi; Sonia Radice
Journal:  Drug Saf       Date:  2015-09       Impact factor: 5.606

2.  Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research.

Authors:  Rachel Huddart; Alison E Fohner; Michelle Whirl-Carrillo; Genevieve L Wojcik; Christopher R Gignoux; Alice B Popejoy; Carlos D Bustamante; Russ B Altman; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-01-21       Impact factor: 6.875

Review 3.  Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.

Authors:  Jacob T Brown; Jeffrey R Bishop; Katrin Sangkuhl; Erika L Nurmi; Daniel J Mueller; Jean C Dinh; Andrea Gaedigk; Teri E Klein; Kelly E Caudle; James T McCracken; Jose de Leon; J Steven Leeder
Journal:  Clin Pharmacol Ther       Date:  2019-04-13       Impact factor: 6.875

Review 4.  Moving pharmacoepigenetics tools for depression toward clinical use.

Authors:  Laura M Hack; Gabriel R Fries; Harris A Eyre; Chad A Bousman; Ajeet B Singh; Joao Quevedo; Vineeth P John; Bernhard T Baune; Boadie W Dunlop
Journal:  J Affect Disord       Date:  2019-02-06       Impact factor: 4.839

5.  Clinical Pharmacology & Therapeutics: Past, Present, and Future.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2017-03       Impact factor: 6.875

Review 6.  Value of Supportive Care Pharmacogenomics in Oncology Practice.

Authors:  Jai N Patel; Lauren A Wiebe; Henry M Dunnenberger; Howard L McLeod
Journal:  Oncologist       Date:  2018-04-05

Review 7.  Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-04-11

8.  How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.

Authors:  Richard J Marrero; Emily J Cicali; Meghan J Arwood; Elizabeth Eddy; David DeRemer; Brian H Ramnaraign; Karen C Daily; Dennie Jones; Kelsey J Cook; Larisa H Cavallari; Kristin Wiisanen Weitzel; Taimour Langaee; Kimberly J Newsom; Petr Starostik; Michael J Clare-Salzer; Julie A Johnson; Thomas J George; Rhonda M Cooper-DeHoff
Journal:  Clin Pharmacol Ther       Date:  2020-07-06       Impact factor: 6.875

Review 9.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

Review 10.  CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.

Authors:  Maxime Meloche; Michael Khazaka; Imad Kassem; Amina Barhdadi; Marie-Pierre Dubé; Simon de Denus
Journal:  Br J Clin Pharmacol       Date:  2020-04-05       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.